. Author manuscript; available in PMC: 2017 Jun 1.

Published in final edited form as: J Thorac Oncol. 2016 Mar 8;11(6):890–899. doi: 10.1016/j.jtho.2016.02.018

Table 1. Patients.

Enrolled	44

Women/Men	22/22

Median Age (Range)	61 (31 – 77)

Karnofsky Performance Status

≥90%	19 (43%)
80%	20 (46%)
70%	5 (11%)

Cigarette Smoking History

Never	7 (16%)
Former	30 (68%)
Current	7 (16%)
Median Pack-Years Smoked (Range)	38 (10 – 120)

Brain Metastases

No	32 (73%)
Yes	12 (27%)
Treated	11 (92%)
Untreated	1 (8%)

Oncogenic Drivers Identified

KRAS^‡	16 (36%)
ALK	3 (7%)
BRAF V600E	2 (5%)
EGFR exon 20 Insertion	1 (2%)
HER2/PIK3CA	1 (2%)
None	15 (34%)
Not Tested	6 (14%)

^‡

KRAS mutations: G12V (N = 3), G12C (N = 7), G12A (N = 2), G12D (N = 3), G13D (N =1)